(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of 11.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Mimedx Group's revenue in 2025 is $352,376,000.On average, 1 Wall Street analysts forecast MDXG's revenue for 2025 to be $55,389,779,521, with the lowest MDXG revenue forecast at $55,389,779,521, and the highest MDXG revenue forecast at $55,389,779,521.
In 2026, MDXG is forecast to generate $63,511,920,200 in revenue, with the lowest revenue forecast at $63,511,920,200 and the highest revenue forecast at $63,511,920,200.